Cargando…

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

BACKGROUND: The incidence and severity of tuberculosis chemotherapy toxicity is poorly characterised. We used data available from patients in the REMoxTB trial to provide an assessment of the risks associated with the standard regimen and two experimental regimens containing moxifloxacin. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tweed, Conor D., Crook, Angela M., Amukoye, Evans I., Dawson, Rodney, Diacon, Andreas H., Hanekom, Madeline, McHugh, Timothy D., Mendel, Carl M., Meredith, Sarah K., Murphy, Michael E., Murthy, Saraswathi E., Nunn, Andrew J., Phillips, Patrick P. J., Singh, Kasha P., Spigelman, Melvin, Wills, Genevieve H., Gillespie, Stephen H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042413/ https://www.ncbi.nlm.nih.gov/pubmed/29996783 http://dx.doi.org/10.1186/s12879-018-3230-6

Ejemplares similares

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study
por: Tweed, Conor Duncan, et al.
Publicado: (2018)

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status
por: Tweed, Conor D., et al.
Publicado: (2019)

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study
por: Murphy, M. E., et al.
Publicado: (2018)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens
por: Phillips, Patrick P. J., et al.
Publicado: (2017)

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
por: Phillips, Patrick P. J., et al.
Publicado: (2016)

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis
por: Murthy, S. E., et al.
Publicado: (2018)

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
por: Phillips, Patrick P. J., et al.
Publicado: (2016)

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis
por: Murphy, Michael E., et al.
Publicado: (2017)

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
por: Tweed, Conor D, et al.
Publicado: (2019)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Clofazimine pharmacokinetics in patients with TB: dosing implications
por: Abdelwahab, Mahmoud Tareq, et al.
Publicado: (2020)

TB Incidence in an Adolescent Cohort in South Africa
por: Mahomed, Hassan, et al.
Publicado: (2013)

Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB
por: Nemes, Elisa, et al.
Publicado: (2020)

Rethinking intercurrent events in defining estimands for tuberculosis trials
por: Pham, Tra My, et al.
Publicado: (2022)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

The Tuberculin Skin Test versus QuantiFERON TB Gold® in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa
por: Mahomed, Hassan, et al.
Publicado: (2011)

Correction: The Tuberculin Skin Test versus QuantiFERON TB Gold® in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa
por: Mahomed, Hassan, et al.
Publicado: (2011)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
por: Mitnick, Carole D., et al.
Publicado: (2023)

Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease
por: Mbelele, P. M., et al.
Publicado: (2022)

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
por: Chen, Ray Y., et al.
Publicado: (2017)

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
por: Ayoun Alsoud, Rami, et al.
Publicado: (2023)

HIV Is Associated with Modified Humoral Immune Responses in the Setting of HIV/TB Coinfection
por: van Woudenbergh, Esther, et al.
Publicado: (2020)

Advances in clinical trial design: Weaving tomorrow’s TB treatments
por: Lienhardt, Christian, et al.
Publicado: (2020)

Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods
por: Svensson, Robin J., et al.
Publicado: (2017)

CAD4TB software updates: different triaging thresholds require caution by users and regulation by authorities
por: Fehr, J., et al.
Publicado: (2023)

Atripla(R)/anti-TB combination in TB/HIV patients. Drug in focus
por: Semvua, Hadija H, et al.
Publicado: (2011)

785. British Transplant ID, Mycology, and Infection in the Immune Compromised Network (BRITMIC) -Addressing the unmet need of Transplant ID in the United Kingdom
por: Stone, Neil R H, et al.
Publicado: (2023)

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

TB Anywhere is TB Everywhere
por: Wortham, Jonathan M.
Publicado: (2018)

TB or not TB! That’s the question
por: Nugud, Ahmed, et al.
Publicado: (2019)

Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting
por: Cates, L., et al.
Publicado: (2021)

Safety and immunogenicity of candidate vaccine M72/AS01(E) in adolescents in a TB endemic setting
por: Penn-Nicholson, Adam, et al.
Publicado: (2015)

COVID-19 vaccine development: What lessons can we learn from TB?
por: Safar, Hussain A., et al.
Publicado: (2020)

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
por: Tameris, Michele, et al.
Publicado: (2014)

The $\beta^{-}$-decay of $^{158}$Tb
por: Von Dincklage, R D, et al.
Publicado: (1985)

C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial
por: Aggerbeck, Henrik, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_is69g0ufrpq7ihuvesljage3fu